WHAT: Website on FDA’s Efforts to Advance Artificial Pancreas Device Systems. Sometimes an artificial pancreas device system is referred to as a “closed-loop” system, an “automated insulin delivery” system, or an “autonomous system for glycemic control.” NOTE: The Artificial Pancreas Device Systems described on this site do not involve biomaterial, synthetic or artificial tissue or organs.
WHY: To advance the development of an artificial pancreas device system, an innovative device that automatically monitors blood glucose and provides appropriate insulin doses in people with diabetes who use insulin.
WHO: FDA along with diabetes patient groups, diabetes care providers, medical device manufactures, and researchers
WHEN: On September 28, 2016, the FDA approved the first hybrid closed loop system, the Medtronic’s MiniMed 670G System, intended to automatically monitor blood sugar and adjust basal insulin doses in people with type 1 diabetes.